MilliporeSigma’s Millicell DCI Digital Cell Imager Offers Quick, Accurate, and Objective Cell Monitoring

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, November 2021
Volume 16
Issue 11

MilliporeSigma’s newly launched Millicell DCI Digital Cell Imager quickly and objectively assesses common cell culture parameters and growth trends for more consistent cell cultures.

MilliporeSigma’s newly launched Millicell DCI Digital Cell Imager instrument helps improve cell culture productivity in the lab by assessing a broad range of parameters, including confluency, morphology, and cell growth trends, which provides a faster and more accurate analysis with reduced user bias, according to a company press release.

Millicell DCI, launched in October 2021, has an intuitive, built-in touchpad display that enables more efficient execution of repetitive daily laboratory techniques associated with cell passaging, screening, or manufacturing of cell-based products. The Millicell Cloud software operates on an off-device subscription and provides automated data analysis. The software also allows for access to the data from remote desktops or mobile devices. The remote feature saves on costs and supports data redundancy for backup as well as protection by automatically sorting and storing data and images. With this instant access to historical data, researchers can track cell culture trends and create consistent cell cultures.

The instrument also removes the requirement for manual manipulation of the cell culture flask, which can result in reduced contamination risk and improved flexibility users. Evaluation is also possible for a wide variety of cell cultures, including adherent cells and cell lines, spheroids, organoids. In addition, the instrument facilitates hemocytometer or in-vessel measurement.

Source: MilliporeSigma

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content